A small study led by investigators from Brigham and Women’s Hospital suggests that the serotonin-norepinephrine reuptake inhibitor (SNRI) venlafaxine hydrochloride may be as effective as low-dose estradiol for relief of hot flashes.
According to a recent study in Menopause, women who go through natural menopause at ages 40 to 45 may be at increased risk of developing heart failure and smoking may produce a similar risk among those who experience menopause at ages 46 to 49.
Early menopause—whether natural or surgical—may be associated with negative effects on cognitive function that are not entirely offset by postmenopausal hormone therapy (HT), according to a new study in BJOG.
A study from The American Journal of Clinical Nutrition is the basis for this article in Woman's Day. A link to the North American Menopause Society’s website is offered in the introduction, but not one to the study abstract itself.
The first drug combining estrogens with bazedoxifene has been approved by the U.S. Food and Drug Administration (FDA) for treatment of moderate-to-severe vasomotor symptoms associated with menopause and prevention of postmenopausal osteoporosis.
On February 26, 2013, FDA approved ospemifene (Osphena, Shionogi Inc.) for the treatment of moderate-to-severe dyspareunia resulting from vulvar and vaginal atrophy associated with menopause. Estrogen levels decline during menopause, resulting in a thinning and drying of vaginal tissues. This atrophy can cause a woman to experience pain during intercourse (dyspareunia).
Estrogen therapy is still the mainstay of therapy for moderate-to-severe symptoms and long-term studies on endometrial safety of local estrogen and ospemifene are lacking. Those are the key conclusions from an updated position statement on management of symptomatic vulvovaginal atrophy (VVA) in postmenopausal women issued by the North American Menopause Society (NAMS).
FDA has approved low-dose paroxetine capsules (Brisdelle, Noven Pharmaceuticals), 7.5 mg/day, for treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause, also referred to as hot flashes and night sweats.